Skip to content

Si-Bone

US · SIBN #3357 by market cap Listed 2018
18.68 -0.42 -2.20%
Live - 5344 symbols - heartbeat 103s ago · 2026-10-08 10:10
Pre-market 19.10 0.00%
After-hours 19.10 0.00%
Market cap
837.21M
P/B
4.59
EPS
-0.44
Reader sentiment Are you bullish or bearish on SIBN?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 4.69 In line with history 63rd percentile
5-year average 4.73 · #89 of 125 in Medical Devices
P/E ratio -57.88 Cheap vs history 1st percentile
5-year average -19.73 · forward -49.03
P/S ratio 4.01 Cheap vs history 32nd percentile
5-year average 5.23 · forward 3.41 · #88 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Si-Bone (SIBN) 837.21M -56.61 4.59 0.00%
Abbott Laboratories (ABT) 168.58B 31.53 3.30 2.50%
Medtronic (MDT) 111.11B 21.39 2.21 3.28%
Stryker Corp (SYK) 104.95B 28.35 4.38 1.27%
Boston Scientific (BSX) 60.86B 17.00 2.44 0.00%
Edwards Lifesciences (EW) 47.61B 48.02 4.48 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value16.69 Economic moatNone UncertaintyHigh

Trading 10.6% above Morningstar's fair value estimate.

Fair value

SI-BONE Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 14% premium over our quantitative fair value estimate of $16.69 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 55.1 sits in the top 10% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.4%, a core component of profitability, sits in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 10:10:53 · For reference only, not investment advice and not tailored to your situation.